Phase 1 Pharmacy Checklist
GMP or Extemporaneous Compounding: What do you need?
Pharmacy Compounding: Clinical Development Efficiencies for Early Phase 1 Studies
Emerging FDA Requirements for Hazardous Drugs
Celerion Pharmacy Services
| Event Details | |
| Dates | March 17-21, 2020 |
| Venue | Marriott Marquis Houston 1777 Walker St, Houston, TX 77010 |
Register today |
|
Kate Reese is an experienced clinical operations leader, specializing in pharmacy services for early clinical development. Kate received her Doctor of Pharmacy degree from the Skaggs School of Pharmacy at the University of Montana. In 2008, Dr. Reese joined Celerion as a Clinical Research Pharmacist, taking on increasing responsibility during her 11 years of managing pharmacy operations at Celerion’s flagship clinical site in Phoenix, Arizona. Kate currently serves as Director, Strategic Initiatives Global Clinical Research for Celerion.
Celerion is a global provider of outsourced clinical development services with the proven ability to address programs from first-in-human (FIH) through Phases I-III. We are the ideal partner for innovative biotech companies in an environment overwhelmed by tightening budgets, stricter regulations and more complex reimbursement. We assist biotech companies in getting their drugs to market faster and more cost effectively.
With offices throughout Europe, the U.S. and Asia, we can address all of your requirements.
We have specifically developed expertise in the areas of Renal/Hepatic impairment, Vaccines, Respiratory and Oncology.
With our years of experience, Celerion has helped clients address their risk management challenges in the face of the increasing complexities of Phase I-III studies.